bexmarilimab 
GtoPdb Ligand ID: 12907
|
Synonyms: Clevegen | FP-1305 | FP1305
Compound class:
Antibody
Comment: Bexmarilimab (FP-1305; Faron Pharmaceuticals) is a humanized anti-CLEVER-1 (stabilin 1; STAB1) IgG4-antibody [1]. It switches immunosuppressive M2 macrophages to immune-stimulating M1 macrophages, activates T cells and restores T cell-dependent killing of cancer cells. Bexmarilimab is a cancer immunotherapy clinical candidate [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Bexmarilimab has a modification in its Fc region that eliminates Fc-mediated effector functions (FcγR binding and complement pathway activation) [1]. |
| Selectivity at other protein targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License